| Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update BJ Schneider, J Naidoo, BD Santomasso, C Lacchetti, S Adkins, ... Journal of Clinical Oncology 39 (36), 4073-4126, 2021 | 1285 | 2021 |
| Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq … MB Atkins, SJ Lee, B Chmielowski, AA Tarhini, GI Cohen, TG Truong, ... Journal of Clinical Oncology 41 (2), 186-197, 2023 | 322 | 2023 |
| Systemic therapy for melanoma: ASCO guideline R Seth, H Messersmith, V Kaur, JM Kirkwood, R Kudchadkar, ... Journal of Clinical Oncology 38 (33), 3947-3970, 2020 | 285 | 2020 |
| Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline BD Santomasso, LJ Nastoupil, S Adkins, C Lacchetti, BJ Schneider, ... Journal of Clinical Oncology 39 (35), 3978-3992, 2021 | 258 | 2021 |
| The consequences of growth of a mutator strain of Escherichia coli as measured by loss of function among multiple gene targets and loss of fitness P Funchain, A Yeung, J Lee Stewart, R Lin, MM Slupska, JH Miller Genetics 154 (3), 959-970, 2000 | 229 | 2000 |
| Epigenetic profiling in chronic lymphocytic leukemia reveals novel methylation targets LJ Rush, A Raval, P Funchain, AJ Johnson, L Smith, DM Lucas, ... Cancer research 64 (7), 2424-2433, 2004 | 186 | 2004 |
| Resumption of immune checkpoint inhibitor therapy after immune-mediated colitis H Abu-Sbeih, FS Ali, AR Naqash, DH Owen, S Patel, GA Otterson, ... Journal of clinical oncology 37 (30), 2738-2745, 2019 | 183 | 2019 |
| In vitro and in vivo studies of MutS, MutL and MutH mutants: correlation of mismatch repair and DNA recombination MS Junop, W Yang, P Funchain, W Clendenin, JH Miller DNA repair 2 (4), 387-405, 2003 | 161 | 2003 |
| Quantitative spatial profiling of PD-1/PD-L1 interaction and HLA-DR/IDO-1 predicts improved outcomes of anti–PD-1 therapies in metastatic melanoma DB Johnson, J Bordeaux, JY Kim, C Vaupel, DL Rimm, TH Ho, ... Clinical Cancer Research 24 (21), 5250-5260, 2018 | 159 | 2018 |
| Microbiomic differences in tumor and paired-normal tissue in head and neck squamous cell carcinomas H Wang, P Funchain, G Bebek, J Altemus, H Zhang, F Niazi, C Peterson, ... Genome medicine 9, 1-10, 2017 | 126 | 2017 |
| Prospective clinical study of precision oncology in solid tumors DPS Sohal, BI Rini, AA Khorana, R Dreicer, J Abraham, GW Procop, ... Journal of the National Cancer Institute 108 (3), djv332, 2016 | 107 | 2016 |
| Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series L Sun, P Funchain, JM Song, P Rayman, C Tannenbaum, J Ko, ... Journal for immunotherapy of cancer 6, 1-7, 2018 | 102 | 2018 |
| Increased incidence of venous thromboembolism with cancer immunotherapy J Roopkumar, S Swaidani, AS Kim, B Thapa, L Gervaso, BP Hobbs, ... Med 2 (4), 423-434. e3, 2021 | 100 | 2021 |
| Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study YG Najjar, K Navrazhina, F Ding, R Bhatia, K Tsai, K Abbate, B Durden, ... Journal for immunotherapy of cancer 8 (1), e000331, 2020 | 99 | 2020 |
| Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival TA Sussman, H Li, B Hobbs, P Funchain, KR McCrae, AA Khorana Journal for immunotherapy of cancer 9 (1), e001719, 2021 | 97 | 2021 |
| Escherichia coli Strains (ndk) Lacking Nucleoside Diphosphate Kinase Are Powerful Mutators for Base Substitutions and Frameshifts in Mismatch-Repair-Deficient … JH Miller, P Funchain, W Clendenin, T Huang, A Nguyen, E Wolff, ... Genetics 162 (1), 5-13, 2002 | 96 | 2002 |
| Phase I clinical trial of combination propranolol and pembrolizumab in locally advanced and metastatic melanoma: safety, tolerability, and preliminary evidence of antitumor … S Gandhi, MR Pandey, K Attwood, W Ji, AK Witkiewicz, ES Knudsen, ... Clinical Cancer Research 27 (1), 87-95, 2021 | 94 | 2021 |
| Systemic therapy for melanoma: ASCO guideline update R Seth, SS Agarwala, H Messersmith, KC Alluri, PA Ascierto, MB Atkins, ... Journal of Clinical Oncology 41 (30), 4794-4820, 2023 | 87 | 2023 |
| Next-generation sequencing (NGS) of cell-free circulating tumor DNA and tumor tissue in patients with advanced urothelial cancer: a pilot assessment of concordance PC Barata, VS Koshkin, P Funchain, D Sohal, A Pritchard, S Klek, ... Annals of Oncology 28 (10), 2458-2463, 2017 | 82 | 2017 |
| Adjuvant pembrolizumab versus IFNα2b or ipilimumab in resected high-risk melanoma KF Grossmann, M Othus, SP Patel, AA Tarhini, VK Sondak, MV Knopp, ... Cancer discovery 12 (3), 644-653, 2022 | 79 | 2022 |
